Recombinant Human Beta Defensin 3

Molecule:

BD-3

Synonyms:

BD-3; HBD3; HBP3; DEFB3; HBP-3; hBD-3; DEFB-3; DEFB103; beta-defensin 3; defensin, beta 3

Species:

Human

Cat. No.:

CRB502A pdf (datasheet)

Quantity/Size:

5 μg

Price:

$190.00 BUY

Description:

Recombinant human Defensin beta 3 contains 45 amino acid residues and is an antimicrobial peptide belonging to the distinct family of beta-defensins.

Background: Defensins (alpha and beta) are cationic peptides with a broad spectrum of antimicrobial activity that comprise an important arm of the innate immune system. The alpha-defensins are distinguished from the beta-defensins by the pairing of their three disulfide bonds. To date, four human beta-defensins have been identified; BD-1, BD-2, BD-3 and BD-4. Beta-defensins are expressed on some leukocytes and at epithelial surfaces. In addition to their direct antimicrobial activities, they are chemoattractant towards immature dendritic cells and memory T cells. The beta-defensin proteins are expressed as the C-terminal portion of precursors and are released by proteolytic cleavage of a signal sequence and, in the case of BD-1 (36 a.a.), a propeptide region. Beta-defensins contain a six-cysteine motif that forms three intra-molecular disulfide bonds. Beta-Defensins are 3-5 kDa peptides ranging in size from 33-47 amino acid residues.

Entrez Symbol:

DEFB103A

Uniprot Name:

Beta-defensin 103

Uniprot ID:

P81534

Data PDF:

CRB502

Source:

E. coli

Molecular Weight:

~5.2 kDa

Formulation:

Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4 + 13 0mM NaCl.

Purity:

>98% by SDS-PAGE and HPLC analyses.

Biological Activity:

Fully biologically active when compared to standard. The ED50 as determined by anti-microbial activity against E.coli. is less than 30 μg/ml, corresponding to a specific activity of > 33.3 IU/mg.

Specific Activity:

> 33.3 IU/mg

Endotoxin Level:

Less than 1EU/μg as determined by LAL method.

Amino Acid Sequence:

GIINTLQKYY CRVRGGRCAV LSCLPKEEQI GKCSTRGRKC CRRKK

Reconstitution:

Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/ml. Further dilutions should be made in appropriate buffered solutions.

Storage/Stability:

This lyophilized preparation is stable at 2-4°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-4°C.